Tumor-infiltrating lymphocytes influence on prognosis and outcome of ovarian cancer

Khatuna Khatchapuridze, Salome Kordzaia, Nino Kekelidze, Zaza Tsitsishvili, Maia Mchedlishvili, Dimitri Kordzaia


Ovarian cancer has the highest case fatality rate among the gynecological malignancies. Most cases of ovarian cancer are diagnosed at an advanced stage. Although more than half of patients are in remission following the “debulking” surgery and first-line platinum-based chemotherapy, the five-year survival rate remains less than 25%. In the case of treatment in the early stages, the 5-year survival rate reaches 90%. No precise prognostic biomarkers for ovarian cancer have been available until the present. At the same time, growing evidence suggests that ovarian cancer is an immunogenic disease that can be identified by the patient's (host) immune system. The interaction between the host immune system and cancer cells is crucial for tumor progression. In recent years, many studies have been devoted to the study of tumor-infiltrating lymphocytes (TILs) in cases of ovarian cancer. The presence of tumor-infiltrating T-cells in ovarian cancer is a clear prognostic indicator and correlates with improved clinical outcomes. It is thought that the presence of tumor-infiltrating CD8 + T cells is associated with improved survival in almost all solid tumor types. Favorable clinical outcome and reliable prognosis, following the “debulking” surgery and adjuvant chemotherapy, is in close correlation with the existence of TILs not only in the cancer tissue but also in its microenvironment.


Ovarian cancer; Tumor-infiltrating T-cells; “Debulking” surgery; Chemotherapy.

Full Text:



Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30)

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47. [Errata, CA Cancer J Clin 2002;52:119, 181-2]

Bowtell DD, Bohm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer, Nat. Rev. Cancer 15 (11) (11 2015) 668–679. [PubMed: 26493647]

Ozols RF. Management of advanced ovarian cancer consensus summary. Semin Oncol 2000;27:Suppl 7:47-9

Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10

Wang W, Kryczek I, Dostal L, et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer, Cell 165 (5 19 2016) 1092–1105. [PubMed: 27133165]

Au KK, Josahkian JA, Francis JA, Squire JA, Koti M, Current state of biomarkers in ovarian cancer prognosis, Future Oncol 11 (23) (2015) 3187–3195. [PubMed: 26551891]

Hennessy BT, Coleman RL, Markman M. Ovarian cancer.Lancet. 2009; 374:1371-1382

Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35

Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-4

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348:203-213

Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, Farooqi AA, Papadia A, Panici PB. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev. 2015; 16:3635-3638

Santoiemma PP, Powell DJ. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015; 16:807-820

Ma D, Gu MJ. Immune effect of tumor-infiltrating lymphocytes and its relation to the survival rate of patients with ovarian malignancies. J Tongji Med Univ. 1991;11:235-239

Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011, 105(1):93–103

Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25(18):2586–2593

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S:Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222(4):350–366

Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, BusundLT: Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011, 6(1):e14611

Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW:Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009, 58(3):449–459

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA2005, 102(51):18538–18543

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1 ligand 1and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104(9):3360–3365

Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009, 4(7):e6412

Wang W, Green M, Rebecca Liu J, Lawrence TS, Zou W, CD8+ T Cells in Immuno-therapy, Radiotherapy, and Chemotherapy, in: Zitvogel L, Kroemer G (Eds.), Oncoimmunology: A Practical Guide for Cancer Immunotherapy, Springer International Publishing, Cham 2018, pp. 23–39

Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31: 443-473

Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015-4022

Han LY, Fletcher MS, Urbauer DL, et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008;14(11):3372-3379

Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393-402

Hwang WT, Adams SF, Tahirovic E, Hagemann IS,Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192-198)

Callahan MJ, Nagymanyoki Z, Bonome T, et al. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin CancerRes. 2008;14(23):7667-7673

Preston CC, Maurer MJ, Oberg AL, et al.The ratios of CD8+ T cells to CD4+ CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One.2013;8(11):e80063

Musrap, N. & Diamandis, E. P. Revisiting the complexity of the ovarian cancer microenvironment—clinical implications for treatment strategies. Mol. Cancer Res. 10, 1254–1264 (2012)

Zsiros, E., Tanyi, J., Balint, K. &Kandalaft, L. E. Immunotherapy for ovarian cancer: recent advances and perspectives. Curr.Opin.Oncol. 26, 492–500 (2014)

Schlienger, K. et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin. Cancer Res. 9, 1517–1527 (2003)

Santin, A. D. et al. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am. J. Obstet. Gynecol. 183, 601–609 (2000)

Zou W, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat. Rev. Cancer 5 (4) (4 2005) 263–274. [PubMed: 15776005]

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH: Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. American journal of clinical oncology 2012, 36(3):224–231

Aaltomaa S, Lipponen P, Eskelinen M, KosmaVM, Marin S, Alhava E, Syrjanen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992, 28A(4–5):859–864

Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. GynecolObstet Invest 2001; 51: 254-61

Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-34

Hayashi K, Yonamine K, Masuko-Hongo K, et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. GynecolOncol 1999; 74: 86-92

Halapi E, Yamamoto Y, Juhlin C, et al. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer ImmunolImmunother 1993; 36:191-7

Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumorinfiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 1993; 12:429-37

Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, EberleinTJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. ProcNatlAcadSci U S A 1995;92:432-6

Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class IIrestricted fashion. Cancer J Sci Am 1996;2: 263

Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptidepulsed autologous dendritic cells.ObstetGynecol 2000;96:422-30

Favero J, Lafont V. Effector pathways regulating T cell activation. Biochem Pharmacol 1998; 56: 1539-47

Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-72,

Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLAclasI expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996;174:116-28

Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS.Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999; 163:6251-60

Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligandexpressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998; 101: 2579-88

Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumorassociated antigen RCAS1. Nat Med 1999;5: 938-4239


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)